Teacher Retirement System of Texas Purchases 5,987 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

Teacher Retirement System of Texas grew its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) by 18.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 38,178 shares of the company’s stock after acquiring an additional 5,987 shares during the quarter. Teacher Retirement System of Texas’ holdings in Denali Therapeutics were worth $778,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Wellington Management Group LLP lifted its position in Denali Therapeutics by 9.2% during the third quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company’s stock valued at $312,491,000 after purchasing an additional 903,683 shares during the period. FMR LLC raised its position in shares of Denali Therapeutics by 3,234.3% in the third quarter. FMR LLC now owns 7,831,378 shares of the company’s stock valued at $228,128,000 after buying an additional 7,596,508 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Denali Therapeutics by 63.2% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company’s stock worth $109,223,000 after buying an additional 1,451,770 shares during the last quarter. Principal Financial Group Inc. grew its holdings in shares of Denali Therapeutics by 13.8% in the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company’s stock valued at $36,076,000 after purchasing an additional 149,939 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Denali Therapeutics by 1.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,028,462 shares of the company’s stock valued at $20,960,000 after purchasing an additional 12,652 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Stock Up 4.1 %

Shares of NASDAQ:DNLI opened at $14.78 on Monday. The business has a 50 day moving average price of $19.05 and a 200 day moving average price of $23.21. The company has a market cap of $2.15 billion, a price-to-earnings ratio of -5.36 and a beta of 1.46. Denali Therapeutics Inc. has a twelve month low of $13.67 and a twelve month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.08. Analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Robert W. Baird started coverage on Denali Therapeutics in a research report on Tuesday, January 7th. They issued an “outperform” rating and a $31.00 target price for the company. Bank of America dropped their price target on Denali Therapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a research report on Monday, March 10th. Stifel Nicolaus raised Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a research note on Monday, December 16th. Baird R W raised shares of Denali Therapeutics to a “strong-buy” rating in a report on Tuesday, January 7th. Finally, Oppenheimer reduced their price target on shares of Denali Therapeutics from $50.00 to $42.00 and set an “outperform” rating on the stock in a report on Monday, March 3rd. Two analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $37.20.

Insider Transactions at Denali Therapeutics

In other news, insider Carole Ho sold 12,255 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $20.22, for a total transaction of $247,796.10. Following the sale, the insider now owns 178,580 shares of the company’s stock, valued at $3,610,887.60. This trade represents a 6.42 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Vicki L. Sato sold 3,080 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total value of $64,402.80. Following the transaction, the director now owns 107,976 shares of the company’s stock, valued at approximately $2,257,778.16. This trade represents a 2.77 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 47,940 shares of company stock worth $973,442. Corporate insiders own 7.90% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.